Boundless Bio, Inc. (BOLD) financial statements and ratios from SEC XBRL: revenue $5.36M (TTM), net margin -1086.4%, revenue growth -32.1% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $5.36M |
| Net Margin | -1086.4% |
| Revenue Growth (YoY) | -32.1% |
| EPS Growth (YoY) | -32.5% |
| FCF Growth (YoY) | -25.5% |
| Price / Book | 1.03 |
| Price / Sales | 17.96 |
| FCF Yield | -150.4% |
| Altman Z-Score | -2.18 (distress) |
| Sector P/E (Healthcare) | 21.7 |
BOLD overview · BOLD earnings · BOLD KPIs · BOLD investor relations · BOLD ownership · BOLD peers · BOLD filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.